SOURCE: Paragon Financial Limited

Paragon Financial Limited

December 05, 2011 08:16 ET

Marina Biotech and OXiGENE Supported by Strong Clinical Programs

The Paragon Report Provides Equity Research on Marina Biotech & OXiGENE

NEW YORK, NY--(Marketwire - Dec 5, 2011) - Despite a volatile market, the biotechnology industry has performed admirably in recent months. In November the sector was supported by victories with encouraging clinical developments, three drug approvals, Gilead's $11 billion acquisition of Pharmasset and two IPOs.The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on Marina Biotech, Inc. (NASDAQ: MRNA) and OXiGENE, Inc. (NASDAQ: OXGN). Access to the full company reports can be found at:

www.paragonreport.com/MRNA

www.paragonreport.com/OXGN

In the third quarter The Biotechnology Industry Organization spent almost $2 million lobbying Congress, the White House, and more than a dozen federal agencies on topics including funding and patent laws. According to the Associated Press, the industry's interests included funding for biofuels projects, funding for the Food and Drug Administration, National Institutes of Health, the Centers for Disease Control and Prevention, emergency preparedness programs, defense from bioterror attacks, patent regulations, renewable fuels, Medicaid rates, investment rules, and tax credits.

The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the biotechnology industry register with us free at www.paragonreport.com and get exclusive access to our numerous stock reports and industry newsletters.

OXiGENE, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics to treat cancer and eye diseases in the United States. For the three months ended September 30, 2011, the Company reported a net loss of $3.5 million or $0.25 per share, compared with a net loss of $13.5 million or $3.47 per share for the comparable three-month period in 2010.

Marina Biotech is a biotechnology company, focused on the development and commercialization of oligonucleotide-based therapeutics utilizing multiple mechanisms of action including RNA interference (RNAi) and messenger RNA translational blocking. Last week the company announced that the NASDAQ Listing Qualifications Panel has granted the Company's request to remain listed on The NASDAQ Global Market and will allow the Company until January 31, 2012 to establish a closing bid price of its common stock of $1.00 or more per share for a minimum of 10 consecutive business days.

The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.paragonreport.com/disclaimer